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Background: Recent efforts in HIV-1 vaccine design have focused on immunogens that evoke potent neutralizing antibody
responses to a broad spectrum of viruses circulating worldwide. However, the development of effective vaccines will depend
on the identification and characterization of the neutralizing antibodies and their epitopes. We developed bioinformatics
methods to predict epitope networks and antigenic determinants using structural information, as well as corresponding
genotypes and phenotypes generated by a highly sensitive and reproducible neutralization assay.
282 clonal envelope sequences from a multiclade panel of HIV-1 viruses were tested in viral neutralization assays with an
array of broadly neutralizing monoclonal antibodies (mAbs: b12, PG9,16, PGT121 - 128, PGT130 - 131, PGT135 - 137,
PGT141 - 145, and PGV04). We correlated IC50 titers with the envelope sequences, and used this information to predict
antibody epitope networks. Structural patches were defined as amino acid groups based on solvent-accessibility, radius,
atomic depth, and interaction networks within 3D envelope models. We applied a boosted algorithm consisting of
multiple machine-learning and statistical models to evaluate these patches as possible antibody epitope regions,
evidenced by strong correlations with the neutralization response for each antibody.
Results: We identified patch clusters with significant correlation to IC50 titers as sites that impact neutralization
sensitivity and therefore are potentially part of the antibody binding sites. Predicted epitope networks were mostly
located within the variable loops of the envelope glycoprotein (gp120), particularly in V1/V2. Site-directed mutagenesis
experiments involving residues identified as epitope networks across multiple mAbs confirmed association of these
residues with loss or gain of neutralization sensitivity.
Conclusions: Computational methods were implemented to rapidly survey protein structures and predict epitope
networks associated with response to individual monoclonal antibodies, which resulted in the identification and deeper
understanding of immunological hotspots targeted by broadly neutralizing HIV-1 antibodies.
Keywords: HIV-1 antibody, Thick patch analysis, Bioinformatics algorithms, Boosting algorithm, Machine learning,
Neutralization, in-silico epitope mapping, Epitope networks, Structural mapping, Sequence and structure analysisBackground
To date, the design of an effective vaccine against Hu-
man Immunodeficiency Virus-1 (HIV-1) remains a chal-
lenge and has failed to produce broad and effective
neutralization responses [1-8]. The design of protective
immunogens is especially challenging due to the high
viral escape rate from immune control [9-11]. Ongoing* Correspondence: mojganhd@yahoo.com
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unless otherwise stated.HIV-1 vaccine research efforts include finding and char-
acterizing broadly neutralizing antibodies (nAbs), and
the epitopes they target [12,13]. Identification of the
antigenic targets of nAbs along with mapping the im-
munologically important residues of known epitopes
that affect neutralization is therefore a major goal of
current HIV-1 vaccine research. The HIV-1 envelope is
highly variable, and as a consequence, identification of
key residues that affect neutralization can be complex.
In some instances, lack of neutralization can be ex-
plained by amino acid changes in the known epitopes,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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neutralization [14]. In addition, many regions outside of the
known epitopes have been shown to affect neutralization
sensitivity [15]. The aim of this study is to develop a com-
putational method for discovering and evaluating “epitope
networks” that we define here as groups of interacting and
variable residues that affect antibody binding.
A key element in successful immune response is the
interaction between foreign antigens and antibodies pro-
duced by the B-cells. The ability to identify and characterize
epitopes on antigen surfaces is important for vaccine de-
sign, the development of antibody therapeutics, and immu-
nodiagnostic tests. In the last decade, significant effort has
been invested to understand the nature and characteristics
of linear epitopes with the goal of developing reliable
methods for predicting them. Many tools of varying utility
were produced and have been reviewed [16]. One signifi-
cant outcome was the realization that there is no single
measurable feature about protein-protein interactions that
is able to reliably predict antibody binding sites. More re-
cently, studies have been performed to address conform-
ational epitope identification and prediction which resulted
in several useful tools. These have been reviewed in detail
by El-Manzalawy [17]. In general, existing methods for pre-
dicting conformational B-cell epitopes can be grouped into
three categories: those that rely upon antigen protein struc-
ture alone [18-20], those that use antigen structure in com-
bination with the antibody peptide sequence [21,22] and
those that map peptide “mimics”, mimotopes, derived from
random peptide libraries to the antigen structure’s surface
[23-26].
In this paper, we describe a novel method that utilizes
the antigen protein structure together with neutralization
titers measured by Monogram Biosciences’ neutralization
assay [9] to predict functional B-cell epitope networks and
key protein-protein interacting residues. Data generated
from Monogram’s neutralization assay has been previously
used by researchers utilizing alanine scanning and various
other lab techniques to characterize monoclonal anti-
bodies (mAbs) [3,4,14,27]. Our goal was to develop a
rigorous computational method that incorporates neutra-
lization sensitivity data from a panel of naturally occurring
viruses, in combination with sequence and protein struc-
ture information, and applies an ensemble of data mining
techniques to enable rapid and accurate prediction of anti-
body epitope networks. We aimed to investigate residues
that can interact with antibodies as a network, and in a
structurally meaningful way. We therefore evaluated enve-
lope sequences grouped into patches of amino acid sites.
These patches were then examined to discover networks
of variable residues that significantly impact neutralization
sensitivity.
Patch analysis has been previously suggested and per-
formed to predict protein-protein interaction sites[28,29]. To identify potential HIV-1 antibody epitope
network residues on the antigen surface, we started with
the common concept of a surface patch, as previously
described [30]. Surface patches are typically defined by
determining the accessible surface area (ASA) of each
residue and taking those positioned above a certain
threshold. These values can be calculated by a number
of tools (DSSP [31] and NACCESS [32] for example)
which use tables of maximum solvent accessibility for
each amino acid in a Gly-X-Gly or Ala-X-Ala tripeptide
configuration in solution. However, work by Singh et al.
[33] in which they examined the surface accessibility of
over 18,000 structures in the protein data bank (PDB),
showed that observed surface accessibility often differed
significantly from the values found in traditionally used
tables [34,35] and that occasionally the use of these
values in a real-world calculation produced a result
where an amino acid had a predicted ASA value of more
than 100%. To address this, Singh et al. developed a
table of highest observed accessibility (HOA) values and
suggested normalizing ASA by HOA to obtain a more
meaningful relative surface accessibility (RSA) [33].
The concept of residue interaction networks (RIN) has
been discussed recently in several publications [36,37].
The principle is based upon the fact that proteins are
not rigid bodies, as in a crystal structure, but rather that
they are for the most part flexible and can change in re-
sponse to their immediate environment. Likewise, in a
protein-protein interaction, the orientation of an inter-
acting residue can be influenced by other, buried, resi-
dues that are immediately below it as well as the
residues located deeper underneath to some extent.
Residue depth has been correlated with several protein
properties, such as stability, and conservation of amino
acids and their types [38]. Pintar et al. [39] defined atom
depth as the distance in angstroms (Å) of a non-
hydrogen buried atom from its closest solvent accessible
protein neighbor. Using this definition, the residue depth
(DPR) of surface residues is defined as 0, and >0 for all
those that are buried. In an examination of structures in
the PDB, it was found that buried atoms tend to cluster
into discrete layers [39]. The first inner layer has a max-
imum DPR of ≈ 1.50 Å, with a second inner layer having
a maximum DPR of ≈ 2.50 Å. It is then possible to use
the mean residue DPR to construct “thick” surface
patches in an attempt to capture key residues from the
RIN that are important in defining a functional epitope.
In this study, we determined relative solvent accessibil-
ity according to the method of Singh et al. [33] when
examining the structural information. Additionally, we
took the RIN data into account by exploring thick
patches with several thresholds for DPR. We generated
structural patches considering the complete information
according to these parameters, and systematically tested
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sponse. Our goal was to identify epitope networks which
correspond to immunogenic regions recognized by nAbs.
We were able to build a bioinformatics process, called
“thick patch analysis” (THIPA), that combines viral se-
quence and structural information as well as neutralization
titers against viruses with a range of HIV-1 subtypes, and
applies an ensemble of machine learning and statistical
models to predict antibody epitope networks. In this paper,
we describe the computational method, and the predicted
epitope networks for 21 HIV-1 mAbs, as well as the results




A recombinant-virus assay involving a single round of
virus infection was used to measure neutralization [9].
Briefly, the HIV-1 env libraries present in patient plasma
or cell culture supernatant were amplified from the source
material and cloned into the env expression test vector.
The cloned env libraries were co-transfected with an env-
deleted genomic vector containing a luciferase repor-
ter and the resulting “pseudotyped” viruses were pre-
incubated for 1 hour with serial dilutions of monoclonal
antibodies (MAb) [3,4] and then used to infect U87 cells
that express CD4 plus the CCR5 and CXCR4 co-receptors
(U87/CD4/CCR5/CXCR4). Neutralizing activity was ex-
pressed as the percent inhibition of viral replication (lucif-
erase activity) at each antibody dilution or concentration
compared to a control culture without antibody. The 50%
inhibition concentration (IC50) was determined and
expressed as the antibody concentration conferring 50%
inhibition (Additional file 1: Figure S1). Since the env li-
braries have mixed nucleotides throughout the gp160 se-
quence reflecting the sequence diversity within the viral
quasispecies, individual clones were selected so that un-
ambiguous sequence from a single gp160 vector clone was
used in the analysis. For clonal selection, the pooled viral
DNA was diluted and used to transform competent E. coli.
For each patient sample, multiple colonies were picked
and screened by a rapid single replication cycle assay.
Multiple clones, totaling more than 850, were screened for
sensitivity to nAbs using 3 broadly neutralizing MAbs
(b12, 2 F5 and PG9) that act on different regions of env.
Clones were selected for this study based on either being
similar to the neutralization sensitivity pattern with the
mAbs, co-receptor tropism and infectivity of the parental
env library or because they differed dramatically from the
phenotype of the library in any of the cited characteristics.
Data set
We obtained a panel containing 282 clonal viruses col-
lected from 175 unrelated patients who submittedsamples for commercial patient testing at Monogram
Biosciences. The 282 clones are of diverse subtypes and
recombinants: 21 subtype A’s, 24 AE’s, 19 AG’s, 55 B’s, 3
BF’s, 32 C’s, 55 D’s, 24 F1’s, 41 G’s, 3 H’s, and 5 subtype
J’s. They also differed in co-receptor tropism with 205
R5-only clones, and 77 non-R5 viruses. All clones were
tested in the neutralization assay, described above, and
IC50 titers were obtained for an array of 21 neutralizing
monoclonal antibodies (b12, PG9,16, PGT121 - 128,
PGT130 - 131, PGT135 - 137, PGT141 - 145, and
PGV04) [40,41].
Virus sequencing and sequence analysis
Clonal sequences were obtained for this virus panel. A
set of 12 primers was used to generate overlapping and
redundant sequences from both DNA strands. The
amino acid sequences were aligned to the gp160 se-
quence of the laboratory reference strain HXB2 (Gen-
Bank accession number K03455), and amino acid
positions were numbered through the alignment with
the reference sequence. HXB2 is commonly used for
alignment and numbering by researchers studying HIV-
1 envelope sequences [14,42,43]. Sequence alignments
were performed using ClustalW2 [44] and key sequence
regions were identified by the profile Hidden Markov
Model (HMM) software hmmscan [45]. A binary repre-
sentation of each sequence was obtained by comparison
to HXB2: positions with amino acids identical to HXB2
were coded as 0 and amino acids different from HXB2
were coded as 1 (Figure 1A). Insertions and deletions
were reported as 1 at the HXB2 position preceding the
gap or insertion.
THIPA process overview
The process of predicting antibody epitope networks is
streamlined into an analysis pipeline called “thick patch
analysis” (THIPA) (Figure 1). The THIPA process is per-
formed as follows: first, patch vectors are generated
based on the structural model and genotype of the anti-
gen; as a second step, statistical and machine learning
analyses are performed to identify significant association
of patch compositions and IC50; third, patches signifi-
cantly correlating with IC50 are aligned by position; fi-
nally, the most frequently occurring residue positions
within all significant patches are mapped onto the struc-
ture and identified as predicted epitope network for the
antibody. These steps are described in details in the fol-
lowing sections.
Patch definition
Surface patches are determined by taking a suitable anti-
gen protein structure and for any given surface residue,
determining which additional residues within a given ra-
dius from the central residue meet the appropriate RSA
Figure 1 THIPA (Thick Patch Analysis): An Automated Epitope Network Prediction Pipeline. A) Patch vector files are generated using
structural, genotypic, and phenotypic data. Subsequently, patches are analyzed by multiple machine learning and statistical methods, and patches
identified as significantly associated with neutralization by all models are selected. B) Significant patches are then aligned by position to identify
residue clusters that are frequently recognized as significant. The overlapping residues identified more frequently than average are reported as
predicted epitope networks and are modeled into the 3D structure (highlighted in this cartoon example in green).
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quently not sequential, but represent a conformation-
dependant surface.
To be able to successfully identify all solvent accessible
residues on the gp120 antigen surface, it is important to
identify a suitable protein structure. Of the more than
24 x-ray structures in the PDB for gp120, PDB ID:
3JWD was selected as being the one with the most full-
length structure. 3JWD represents the structure of the
HXB2 sequence simultaneously bound by CD4 and the
48D Fab. However, the 3JWD model, like most crystal
structures, contains truncated regions representing the
variable loops. Therefore, theoretical structural predic-
tions of the full-length HXB2 gp120 molecule were
made by applying the program CPHmodels 3.2 [46]
(http://www.cbs.dtu.dk/services/CPHmodels/).
The quality of the predicted model was assessed by
creating an alignment of the α-Carbon backbones of
PDB ID: 3JWD and the prediction using the DaliLiteserver. [http://www.ebi.ac.uk/Tools/dalilite]. The CPH-
model construct showed minor overall deviation
through the core gp120 region with a root-mean-square
deviation (RMSD) of 1.1 (Additional file 1: Figure S2).
This model was used as a reference structure to deter-
mine patch regions.
Initial surface accessibility calculations were performed
upon protein models with DSSP (http://mrs.cmbi.ru.nl/
hsspsoap/). The ASA values from DSSP were then nor-
malized according to the method of Singh et al. [33]
(http://hoa.netasa.org) to calculate the relative surface
area (RSA) where
RelativeSurfaceArea RSAð Þ ¼
AccessibleSurfaceArea ASAð Þ
HighestObservedArea HOAð Þ
The HOA values for each amino acid were derived in
2009 by Singh et al. [33] from an examination of the
high quality structures present in the PDB. Surface
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whose RSA was > = 20%.
Mean residue depth (DPR) is the mean distance be-
tween all of the atoms in a residue of interest and the
nearest neighboring water molecule on the protein sur-
face [39]. The mean residue depth for each gp120 model
structure was calculated according to the method of Pin-
tar et al. [39] using the tool provided at (http://hydra.
icgeb.trieste.it/dpx) with a sphere radius of 1.4 Å.
In order to try and capture all of the key residues that
may affect a competent antibody epitope, we evaluated
“thick” surface patches. By combining RSA and DPR in-
formation during the patch identification process, we
hope to capture a significant portion of the residue
interaction network (RIN) [36,37] that influences residue
orientation relative to the protein surface and have the
potential of becoming eventually exposed themselves,
given that proteins are dynamic structures and can
change shape when bound to other proteins. To assure
the inclusion of residues that may be part of the RIN, we
examined patches within dimensions that make bio-
logical sense with respect to the size of an antibody foot-
print. We explored 3 different patch radii (8, 10, and
12 Å), as well as four different thresholds for maximum
residue depth (0, 1.5, 2.5, and 3 Å). The patch lists were
generated based on all these conditions -defined by RSA
and DPR parameters-. The program generates a list of
patch sequences, with each sequence consisting of
named positions (e.g. N160) that are included in the
patch. This patch list was then used in subsequent steps.
Creation of patch vectors
In the next step, the matched phenotypes and genotypes
of all viruses were formatted into patch vector files, with
the patch topology established according to the predefined
conditions (Figure 1A). For each antibody, a series of these
patch vector files are generated, one file per patch. Each
file contains the following for all viruses: the virus ID, IC50
measurement of the antibody under investigation, and a
vector of binary (0 or 1) values representing mutations of
the patch residues in that virus. The 0/1 vector is deter-
mined by comparing each position in the patch sequence
to the reference; 0 if identical, 1 if different. Due to the
high-dimensionality of the data, incorporating the individ-
ual amino acid changes was not computationally feasible.
Additionally, since our goal was to identify key regions
likely to be immunological hotspots, using the exact
amino acid at each site as opposed to a binary (0/1) repre-
sentation of the mutation wasn’t expected to make a sig-
nificant difference in the outcome of the study.
Data mining process
Using the patch vector files as input, we performed stat-
istical and machine-learning techniques to correlate theneutralization response as measured by the IC50 (Add-
itional file 1: Figure S1) with the genotype. We devel-
oped a boosted algorithm consisting of four multivariate
and univariate models: multiple linear regression (MLR),
logistic regression (LR), support vector machine (SVM),
and Fisher’s exact test (FET). Data mining was per-
formed in R [47] (http://www.R-project.org).
MLR was applied to the mutations in each patch cap-
tured as 0/1 vectors correlating the amino acid compos-
ition to the IC50 as a continuous measurement. We also
developed 3 other models for correlating the neutrali-
zation response as a binary measurement with the patch
vectors. We classified virus’ neutralization sensitivity
against each antibody as response or no-response corre-
sponding to IC50 < or > highest tested concentration, re-
spectively (Additional file 1: Figure S1). Two multivariate
models were built using LR and SVM techniques for per-
forming classification in order to predict the antibody re-
sponse. The SVM model was trained using libsvm in R
package e1071 utilizing the linear kernel, 20-fold cross-
validation, and cost = 1 [48] (R package version 1.5-26).
Fisher’s exact test was also utilized as a univariate analysis
calculating odds-ratio and statistical significance (p-value)
to identify strong associations between presence or ab-
sence of a mutation with the neutralization response.
These data mining models were applied to all sets of
patch vectors, each set corresponding to a particular anti-
body. Patches that included statistically significant (p-
value < 0.05) amino acid sites by MLR, LR, or FET, or
achieved an overall accuracy of >70% by SVM cross-
validation, were marked as significant and were considered
for further evaluation. Notably, no correction for multiple
testing was performed, as the goal was to be inclusive for
discovering the most potential antibody targets. Only
patches identified as significant by all four methods were
used, with the hypothesis that patches with highest agree-
ment by multiple models would be more likely to be sub-
stantially affecting the neutralization sensitivity, and
therefore, more probable to be part of an epitope or epi-
tope network.
In each significant patch, residues with significant cor-
relation with the neutralization response identified as p-
value < 0.05 were highlighted and stored as regions that
are impactful with regards to the neutralization response
to the antibody.
Identification of epitope networks
We examined a set of conditions for patch composition,
as defined by the particular patch radius and thickness.
Patch radii 8, 10, and 12 Å in combination with depths
of 0, 1.5, 2.5, and 3 Å were investigated. We then se-
lected the condition that included residues previously re-
ported to be part of known antibody epitopes [3,4,27,42]
and by eliminating conditions that resulted in redundant
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lected condition, and evaluated by the four data mining
models. We obtained patches determined to be signifi-
cant by all four models, i.e. patches that contain statisti-
cally significant residues by MLR, LR, and FET, and high
concordance of the neutralization activity with the pre-
dicted response by SVM. To identify frequently occur-
ring clusters of residues in these key patches which are
likely to be important in antibody binding as a network,
the frequency of occurrence of each residue across the
significant patches was obtained (Figure 1B). We noticed
that frequencies were not consistently high or low for
different antibodies, and that the highest observed fre-
quency varied considerably amongst these patches. Thus,
in order to allow a consistent comparison across all
patch sets for different antibodies, the frequency of each
patch cluster was normalized by the frequency of the
most commonly occurring residue (normalized fre-
quency = frequency/max(frequency)). Finally, the resi-
dues occurring with an above average normalized
frequency (>50%) in the significant patches were identi-
fied as epitope network candidates for the particular
antibody.
Structural mapping of potential epitopes
In order to visualize the spatial organization of the
amino acids composing an epitope network, residues
were mapped onto the surface of the CPH-model of
gp120 protein monomer using Chimera [49]. Given the
unique quaternary structure of gp120, residues were also
modeled onto a theoretical gp120 trimer structure to
provide a method for evaluating candidate epitope net-
works arising from potential protein-protein interfaces.
Predicted epitope networks were then visually evaluated
through comparison with known epitopes or superim-
posed upon other gp120 crystal structures (PDB ID:
2NY7) which contained additional interacting molecules
such as the b12 fab and CD4 to evaluate the accuracy of
the epitope network prediction.
Evaluation of the results
In order to evaluate the validity of the predicted epitope
networks, site-directed mutagenesis (SDM) experiments
were performed. Mutations were introduced using two
steps polymerase chain reaction (PCR). In the first step,
the desired mutation is introduced by a PCR primer
used to amplify one part of the target gene. In the sec-
ond step, this PCR product is used as a megaprimer to
amplify the full gene containing the mutation. All muta-
tions were confirmed by sequencing. Since the goal was
to interrogate genotypic reasons for IC50 differences
within viruses that are more likely to be circulating nat-
urally, we used selected clones from our virus panel as
the backbone. We compared the sequences of the clonesfrom a single infected individual that exhibited different
IC50 responses to one or more mAbs. We then selected
clones from the same donor where the sequence differ-
ences overlapped, at least partly, with the predicted epi-
topes for that mAb. There were other sites that differed
between the clones that were outside of the predicted
epitopes. The SDM experiments were designed to intro-
duce mutations at the sites that were different between
the clones and were within the predicted epitopes. We
wanted to investigate whether neutralization sensitivity
can be restored in a resistant clone, or reverted back in a
sensitive clone by introducing mutations at these se-
lected sites. We ran these SDMs using Monogram’s
neutralization assay [9], and obtained IC50 values
against the mAbs under investigation.
Additionally, performance of the THIPA method was
evaluated by developing a prediction model based on the
subset of the residues that were identified to be signifi-
cant by all four data mining models. We built an SVM
model using only these significant sites as input to pre-
dict neutralization sensitivity to each antibody. We then
examined its overall accuracy by comparing the pre-
dicted response to the measured antibody titer classified
into positive or negative, corresponding to IC50 > or <
max tested antibody concentration, respectively (Add-
itional file 1: Figure S1). We obtained sensitivity (true
positive rate) and specificity (true negative rate) for de-
tection of resistance to the particular antibody. In order
to assure that the viral subtype doesn’t impose a bias in
terms of performance characteristics of the algorithm,
we also examined the accuracy of the predictions within
different subtypes. To make sure we have sufficient sam-
ple size for this analysis, only subtypes with at least 10
samples were included (A, AE, AG, B, C, D, F1, and G).
Additionally, we studied previously published epitopes
[4,27] and compared those with the identified epitope
networks by the THIPA process.
Results
In this paper, we present a novel method called thick
patch analysis (THIPA) for predicting antibody epitope
networks by correlating neutralization phenotype to the
genotype and the antigen structure. We define an epi-
tope network as a patch of residues that are antigenic
determinants and have significant association with the
neutralization response. Neutralization sensitivity for 21
HIV-1 monoclonal antibodies (b12, PG9,16, PGT121 -
128, PGT130 - 131, PGT135 - 137, PGT141 - 145, and
PGV04) was determined by Monogram’s neutralization
assay [9] and was captured as IC50 titers against a panel
of 282 clonal viruses. Viral gp120 sequences were
mapped onto structural patches and were then corre-
lated with the neutralization response of these anti-
bodies. Using data mining techniques, we identified
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and are therefore considered to be potential antibody
targets. For validating this method, we performed site-
directed mutagenesis (SDM) experiments using the resi-
dues predicted to be part of the epitope network of mul-
tiple nAbs. Additionally, we used the identified set of
significant residues as input, and built SVM models to
perform prediction of the neutralization response, and
evaluated the accuracy of the predictions. The predicted
epitope networks were also compared with the available
literature on PG9, PG16 and PGV04.
Predicted epitopes
The pipeline generated 268 unique patches on the gp120
surface using the theoretical model structure as a Tem-
plate. A number of these patches were found to be sig-
nificant, as identified by >70% accuracy by SVM or
containing residues that are significantly associated with
the neutralization response by MLR, LR, or FET. Several
of these significant patches were identified by all four
models, and were considered to be highly impactful. The
number of significant patches varied depending on the
monoclonal antibody (mAb). Some of these mAbs could
be grouped into families as they originated from the
same donor: PG-9 and −16, PGT-121-131 135–137, and
PGT-141-145 [40,41].
We investigated the results across several patch depths
and thicknesses, and selected an optimal condition by
examining for coverage and redundancy as well as taking
the theoretical size of an antibody footprint into ac-
count. Patch depths 1.5, 2.5, and 3 Å generated very
similar compositions of residues, and depth = 0 Å in-
cluded no known epitope residues. We selected radius =
12 Å and depth = 2.5 Å as the optimal condition, and
are reporting the final results retrieved based on this
condition. The predicted epitope networks were spatially
oriented into overlapping or neighboring clusters of resi-
dues, and shown in Figure 2. Remarkably, among all sig-
nificant patches for these mAbs, the most frequently
occurring residues were predominantly located within
the variable loops V1/V2 of gp120. This finding is con-
sistent with previously identified epitopes, in particular
for PG-9 and −16 [4,50,51].
Subsequently, the identified epitope network residues
based on the optimized condition were mapped onto the
theoretical full-length gp120 CPH-model, and displayed
in Figure 3. Notably, when the predicted epitope net-
works for PG9 and PG16 were modeled on the surface
of the CPH-model structure together with the published
residues [4], we observed considerable overlap as shown
in Figure 4. This demonstrates that the THIPA method
can be utilized to narrow down the search for antibody
epitopes into key regions that are most likely to be in-
volved in antibody binding, both directly in an epitopeand indirectly as affecting epitope shape or function.
These epitope networks are then candidates for confirm-
ation by site-directed mutagenesis to identify potential
vaccine immunogen constructs.
Site-directed mutagenesis experiments
We selected a subset of the residues within the predicted
epitope networks that were identified for PG9 and
PG16, and performed site-directed mutagenesis (SDM)
experiments using clones that differed in these positions.
We used a resistant or sensitive clone as the backbone,
and examined if sensitivity can be restored or reduced,
respectively, by introducing mutations at the sites of the
predicted epitope networks. Clone pairs 4 and 7 (CL4
and CL7) as well as 16 and 3 (CL16 and CL3) that are
from the same donor were selected. CL4 and CL16 had
resistant IC50 titers against PG9 and PG16, and CL7
and CL3 were sensitive (Figure 5, Additional file 1: Table
S1). Notably, these selected clones had no mutation at
some of the signature sites such as positions 156–162
[4].
As displayed in Figure 5 and Additional file 1: Table
S1, sensitivity of CL4 to PG9 could be restored by intro-
ducing a Q-to-K mutation at position 169 (numbering
provided based on the gp120 of HXB2 reference). Sensi-
tivity could be further enhanced by additional mutations
S173Y and R178K. No increase in the neutralization sen-
sitivity to PG16 was observed with these mutations. We
observed a major loss of the neutralization sensitivity to
PG9 and PG16 in CL7 when introducing the reverse
mutation K169Q, as well as in combination with Y173S
and K178R. CL3 which was sensitive to both PG9 and
PG16 became less sensitive with the introduction of mu-
tations R169T and R169T + D185G. On the flip side, the
resistant clone CL16 gained sensitivity to PG9 and PG16
with the reverse mutations T169R and T169R + G185D.
Notably, 185 as a single mutation had no significant im-
pact on the IC50 titers against PG9 and PG16, however,
as shown in Table S1, response to b12 was positively im-
pacted by D185G and negatively by reverse mutation
G185D; 185 was indeed part of the predicted epitope
network of b12.
Since these positions were predicted to be part of the
epitope networks for a big group of the mAbs (in par-
ticular, 169 is predicted for b12, PG9, PG16, PGT125,
PGT137, PGT142-145, as well as PGV04), IC50 titers of
these SDMs against all the mAbs under investigation are
shown in Table S1. Though, we did not expect that these
particular SDMs would necessarily impact sensitivity
against other mAbs, since the subset of sites selected for
interrogation was based on the predicted networks for
PG9 and PG16. Thus, the possibility of other differing
sites between the clones that happen to be critical for
other mAbs could not be eliminated.
Figure 2 Predicted Epitope Network Residues for all mAbs. The amino-acid composition of the predicted epitope networks is noted as the
prefix of the position on top of each array (for example, N160 indicates Asparagine at position 160 of gp120). Residues marked with “E” are
predicted to be part of the antibody epitope network. The residues that are highly significantly associated with antibody response (MLR p-value <0.001)
are marked by *. Residues reported by Walker et al. to impact PG9 and PG16 sensitivity [4] and those identified by Falkowska et al. for PGV04 [27] are
color-coded in blue.
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We obtained performance characteristics for the THIPA
method by building predictive models based only on the
significant residues identified by all four models, and
assessed the accuracy as the ability to correctly predict
neutralization response. We also examined concordance
of the predictions with the neutralization sensitivity
within each subtype. We obtained concordance rate
within a subtype as the number of true positive and
negative samples divided by total, and calculated thestandard-deviation between accuracy measurements
across the different subtypes. These results are shown in
Table 1. In general, concordance of the neutralization
sensitivity with the predicted response by the algorithm
as obtained from the SVM cross-validation accuracy was
high (>80%) for all antibodies. This suggests that the
THIPA process could successfully identify significant
residues associated with antibody binding, since only a
small subset of all residues was used as SVM input and
not the whole sequence. Notably, this high accuracy was
Figure 3 Predicted Epitope Networks for all mAbs in 3D. Predicted epitope networks are indicated in red for each antibody. The 3D models
represent a theoretical view of full-length HXB2 gp120 monomer by the CPHmodels program [46]. Model is rotated for each antibody to show
the best view of network residues. Visualizations were generated using UCSF Chimera [49]. INSET: General location of the variable regions V1, V2,
and V3 are indicated. Notably, the most overlapping residues between the predicted epitope networks of different mAbs were predominantly
located within the variable loops V1/V2 of gp120.
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http://www.biomedcentral.com/1471-2105/15/77maintained within all different subtype groups, as dem-
onstrated by the narrow range of standard-deviations
[2.42 - 10.35].
Discussion
We describe here a novel multi-modal method for pre-
dicting antibody-specific epitope networks, utilizing anti-
gen structure models, viral genotypes, neutralization
assay results, and data mining techniques, together in a
pipeline called thick patch analysis (THIPA). The goal of
this study was to identify epitope networks of HIV-1
broadly neutralizing antibodies (nAbs). The predicted
epitope networks are clusters of antigenic residues sig-
nificantly associated with binding and neutralization ac-
tivity. We aimed to identify both conformational and
linear epitopes by systematic mapping of the genotypic
information onto 3D structural models and correlating
that with the neutralization phenotype. For this purpose,we utilized the IC50 measurements of 21 monoclonal
antibodies against a panel of 282 clonal HIV-1 viruses of
various subtypes, co-receptor tropism, and neutralization
sensitivity. Patches with a particular thickness and radius
were identified on the HXB2 gp120 theoretical structure,
and the genotype of each virus was mapped onto these
models. The viral sequence located in each patch was
captured as a binary (0/1) vector, representing presence
(1) or absence (0) of a mutation as compared to HXB2.
We then correlated these vectors with the IC50 data by
performing multiple statistical and machine-learning
methods, and identified residues and patches significantly
associated with the neutralization response to each anti-
body. Finally, we evaluated the significant patches detected
by the data mining tools, and predicted epitope networks
for HIV-1 monoclonal antibodies (mAbs).
The THIPA pipeline attempts to identify regions
within the viral envelope that are likely to be targeted by






Predicted PG9 / gp120 Interacting Residues
S158, S162, G167, K168, V169, Q170, K171, E172, Y173, A174, F175, F176, Y177, K178, D185, D187, T188, V200, I201, N300,





Predicted PG16 / gp120 Interacting Residues
Figure 4 Predicted Epitope Network Residues vs. Published Epitopes for PG9 (top panel) and PG16 (bottom panel). Residues predicted
to be part of an interacting network are represented by ball-and-stick and are colored red. Residues reported by Walker et al. to impact PG9 and
PG16 sensitivity [4] are colored blue. Overlap between predicted and published residues is indicated by blue residues which are also shown in
ball-and-stick representation. The 3D models represent a theoretical view of full-length HXB2 gp120 as generated by the CPHmodels program
[46]. A and B depict a hypothetical trimer seen from the top and side respectively, while C and D represent a monomer representation seen from
the front and back respectively. Correct orientation of trimer subunits was obtained by aligning the Cα backbone of the predicted models with
the corresponding chains of the trimer structure (PDB ID: 2NY7). Visualizations were generated using UCSF Chimera [49].
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http://www.biomedcentral.com/1471-2105/15/77nAbs, and therefore are critical to be studied for suc-
cessful vaccine design. This computational method scans
the gp120 molecule through patches with a probable size
for an antibody footprint, and as such, it not only allowsthe examination to be applied in a structurally meaningful
way, but also narrows down the search dimension to
smaller area that is more computationally feasible to sur-
vey. The process utilizes sequences of naturally circulating
Figure 5 Site-Directed Mutagenesis: PG9 (A) and PG16 (B) IC50 titers for clones after introducing mutations into sites identified to be part of
the predicted epitope networks. The dots show the IC50 of the original clone, and the arrows show the IC50 of the mutant. Red dots and higher
IC50 measurements indicate reduced sensitivity, and green dots and lower IC50 titers increased sensitivity. Clones 4 and 7 (CL4 and CL7) are from
the same donor, as well as clones 16 and 3 (CL16 and CL3).
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http://www.biomedcentral.com/1471-2105/15/77viruses, rather than lab strains, which are more likely to be
exposed to nAbs and thus, could elicit their escape mech-
anism. Additionally, this method allows the study ofgenotypic patterns and their impact on neutralization in
context of co-occurring mutations [52]. One of the major
data components included in this method is derived from



































b12 61 221 98.2 77 93.6 4 14 90.5 91.7 89.5 92.7 96.9 94.5 100 92.7 3.47
pg16 177 105 74.3 93.2 86.2 27 12 90.5 83.3 94.7 89.1 75 89.1 83.3 82.9 6.10
pg9 178 104 64.4 94.4 83.3 37 10 85.7 91.7 94.7 87.3 71.9 81.8 83.3 75.6 7.65
pgt121 165 117 88 97.6 93.6 14 4 100 100 100 90.9 90.6 90.9 91.7 95.1 4.45
pgt122 150 132 88.6 92 90.4 15 12 95.2 100 89.5 90.9 90.6 85.5 83.3 92.7 5.26
pgt123 159 123 82.9 93.1 88.7 21 11 85.7 100 84.2 89.1 93.8 87.3 83.3 87.8 5.54
pgt125 130 152 90.8 82.3 86.9 14 23 76.2 87.5 89.5 90.9 87.5 92.7 91.7 78 6.25
pgt126 149 133 89.5 79.2 84 14 31 85.7 91.7 78.9 83.6 78.1 87.3 91.7 78 5.71
pgt127 118 164 87.2 82.2 85.1 21 21 90.5 87.5 94.7 80 78.1 90.9 87.5 82.9 5.74
pgt128 173 109 64.2 92.5 81.6 39 13 81 66.7 94.7 83.6 87.5 89.1 70.8 70.7 10.11
pgt130 146 136 82.4 87.7 85.1 24 18 81 87.5 78.9 85.5 84.4 87.3 87.5 82.9 3.23
pgt131 101 181 90.6 76.2 85.5 17 24 85.7 79.2 78.9 89.1 96.9 80 87.5 80.5 6.33
pgt135 66 216 98.1 77.3 93.3 4 15 95.2 100 89.5 98.2 87.5 94.5 87.5 92.7 4.72
pgt136 31 251 99.2 77.4 96.8 2 7 100 100 94.7 98.2 90.6 98.2 100 92.7 3.67
pgt137 31 251 100 61.3 95.7 0 12 100 100 94.7 94.5 93.8 96.4 95.8 95.1 2.42
pgt141 121 161 92.5 90.1 91.5 12 12 66.7 95.8 84.2 94.5 93.8 98.2 83.3 92.7 10.35
pgt142 139 143 90.9 89.9 90.4 13 14 100 83.3 89.5 87.3 90.6 90.9 91.7 95.1 4.98
pgt143 140 142 89.4 92.9 91.1 15 10 95.2 79.2 94.7 92.7 84.4 87.3 95.8 100 6.91
pgt144 73 209 96.7 86.3 94 7 10 100 91.7 94.7 92.7 93.8 96.4 87.5 95.1 3.64
pgt145 132 150 89.3 91.7 90.4 16 11 85.7 87.5 84.2 90.9 93.8 90.9 91.7 95.1 3.84
pgv04 216 66 72.7 95.4 90.1 18 10 85.7 95.8 84.2 94.5 90.6 89.1 95.8 82.9 5.22
Comparing the predicted neutralization sensitivity of the SVM models using only the significant sites within gp120 as input, to the measured antibody response.
We obtained sensitivity and specificity for detection of resistance to the particular antibody. Overall accuracy of the predictions in the whole dataset as well as
within each subtype was determined. Standard-deviation of % accuracy across those subtypes is shown in the last column.
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http://www.biomedcentral.com/1471-2105/15/77a cell-based neutralization assay that determines the
phenotype of the antibody in presence of a given virus.
Consequently, residues that are identified as significant
can elicit mechanisms of viral escape from the immune re-
sponse. Another key aspect in the design of this method is
the implementation of a boosted technique, which utilizes
an ensemble of statistical and machine-learning models,
each with unique set of strengths, allowing us to evaluate
the network of information from different angles. Notably,
since our purpose of applying these models was to dis-
cover potential immunological hotspots, and not to build
a predictive algorithm, no fine-tuning of the model param-
eters was necessary. In particular, SVM accuracy cutoff of
70% using a linear kernel and default parameters allowed
successful identification of significant patches without fur-
ther parameter adjustment.
In order to examine the validity of our results and ensure
that the identified residues are in-fact related to the
neutralization activity, we performed site-directed mutagen-
esis (SDM) experiments using clones that differed in the res-
idues identified to be part of the predicted epitope networks
of a group of mAbs. The SDM results confirmed significantassociations between a set of residues we investigated and
the antibody response, suggesting that the THIPA method
was able to correctly identify key residues out of many mu-
tations. This is also remarkable given that there were many
other sites that differed between the clones. The inclusion of
mutation 169R in the envelope protein of a neutralization-
resistant virus greatly increased the sensitivity to PG9 and
PG16, suggesting that the normally shielded regions of the
protein were made accessible to the antibody by this change.
The mutation 169 K resulted in an either enhanced or re-
duced susceptibility to a number of mAbs. The reverse mu-
tations K169Q and Y173S had much more dramatic effect
on the neutralization activity against PG9 and PG16 mAbs
than the Q169K and S173Y mutants. This might be due to
the presence of Glutamine and Serine that help shield the
neutralizing epitopes in the specific backbone. Although po-
sitions 178 and 185 were predicted to be significant for a
group of mAbs, introducing mutations at these sites didn’t
affect the IC50 titers significantly suggesting that additional
sites have to be involved in the antibody binding. One possi-
bility is that multiple amino acid changes might modify the
overall shape of the envelope protein, thus exposing
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http://www.biomedcentral.com/1471-2105/15/77normally hidden regions in the HIV-1 envelope protein to
the antibodies. Additional experimental studies would be re-
quired in order to confirm the impact of the newly identified
residues.
For validating our results, we also developed computa-
tional models based only on the subset of significant res-
idues. As shown by the high predictive accuracy of these
models in Table 1, the identified residues were found to
substantially impact the neutralization sensitivity of the
respective antibody. Predictive accuracy was also shown
to be high across the different subtype groups, suggest-
ing that subtype was not a confounder with respect to
the quality of the predictions.
Additionally, we evaluated the structural implications
of our results and compared them with the published lit-
erature. We demonstrated that this method can accur-
ately identify previously published epitope regions of
three HIV-1 mAbs (PG9, PG16, and PGV04), and pro-
vide information on other regions that may contribute
to neutralization response or the corresponding escape
mechanism. The predicted epitope network residues for
PG9 and PG16 together with their published epitopes
depicted on the trimer structure are shown in Figure 4.
The trimer view is provided since both nAbs PG9 and
PG16 belong to the family of quaternary-structure-
specific antibodies [53].
It should be noted that the structural component of the
THIPA process is fairly robust with regard to the structural
model used. We compared the patch lists derived from the
truncated gp120 monomer structure (PDB ID: 3JWD) and
those derived from our full length predicted monomer
structure (data not shown). Excluding sequence regions that
are clipped in the 3JWD structure, there was a high degree
of agreement in the patch definitions. We would predict that
the differences in specifics of loop structure prediction
would not significantly change patch definitions because
they would always be defined as surface residues. However,
if two core structures with different conformations were
used (e.g. prefusion gp120 vs . postfusion gp120), then we
would predict some unique patches would arise from that
and potentially change epitope network prediction outcomes
slightly.
Since the goal of this process was to maximize the
ability to detect disparate potential antigen binding sites,
it is critical to use diverse viruses with naturally occur-
ring variants. We used 282 clones that differ widely in
neutralization sensitivity, co-receptor tropism, and sub-
type. However, there remain residues that are conserved
across all clones, so their impact as antigenic determi-
nants could not be evaluated. Accordingly, a caveat of
utilizing a limited set of viruses for the THIPA method
is that the data mining processes are unable to find po-
tential epitope network residues if there are no muta-
tions in any of the sequences at that particular position.For example, b12 and PGV04 are known to rely on mak-
ing a salt-bridge with D368 [54] but that position is
completely conserved in our virus panel and therefore
could not be identified for either antibody. We recognize
that our method is relevant for identifying highly vari-
able regions associated with antibody neutralization
(Additional file 1: Figure S3). Another limitation of this
method is in detecting binding sites where low level mu-
tations can be tolerated by the antibody, and therefore,
may not be associated with a significant change in IC50.
There may be other viral properties, such as number
of glycosylation sites [42], that can impact the neutra-
lization response and haven’t yet been explored by this
method. Including a broad spectrum of viral sequences
and all possible genotypic determinants into the analysis
is likely to increase the accuracy of the results. Also
noteworthy is the fact that we used a theoretical model
in our study in order to overcome the barrier of trun-
cated variable loops in the available x-ray structures. Al-
though the chosen model had minor deviations from the
actual crystal structure (Additional file 1: Figure S2), and
it is a reasonable assumption that the variable loops can
be flexible in space and thus not requiring to conform to
a fixed structure, it will be beneficial and interesting to
repeat the study using full-length crystal structures as
they become available. An example of the risk associated
with using a theoretical model is N332 for PGT121
which was reported by Julien et al. [55]. In the theoret-
ical model, the angle of the N332 is rotated inward and
only the tip of the residue presents a surface, so the site
didn’t make the depth cutoff in our method. Notably,
other regions do overlap between our predictions and
the reported PGT121 epitope, particularly regions in V3,
for instance N301.
Conclusions
Despite the limitations, the thick patch analysis method can
provide a useful tool to rapidly and automatically scan pro-
tein structures and identify epitope network regions associ-
ated with neutralization response. Our novel in-silico
prediction method narrows down the search space for im-
munological hotspots to key variable regions. These regions
are then good candidates for further evaluation by experi-
mental studies as HIV-1 neutralizing antibody epitopes. Fur-
thermore, this method can be adapted into other disease
areas, particularly for predicting epitopes of highly variable
viruses.
Additional file
Additional file 1: Figure S1. IC50 Curves: neutralization sensitivity is
classified into response (e.g. the right curve) or no-response (e.g. the left
curve) corresponding to IC50 < or > highest tested concentration, respectively.
Figure S2: Actual versus Theoretical Structure: PDB ID: 3JWD (actual) and CPH
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http://www.biomedcentral.com/1471-2105/15/77(theoretical) structure models are shown. Truncated regions in the actual model
are circled by yellow dotted line. Figure S3: Amino-Acid Variability in the Clonal
Sequences for PG9 and PG16 Epitope Network Sites: residues identified within
PG9 and PG16 epitope network can be strongly variable. Observed amino acids
at these sites are displayed as a color-coded bar chart, with every color corre-
sponding to one amino acid according to the left legend. Insertion is marked
as “Z” and deletion is marked as “^”. Table S1: Site-Directed Mutagenesis: IC50
titers against 21 mAbs after introducing mutations into sites identified to be part
of the predicted epitope networks. Clones 4 and 7 (CL4 and CL7) are from the
same donor, as well as clones 16 and 3 (CL16 and CL3).
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